Synthesis and biological and physico-chemical characterization of glycodendrimers and oligopeptides for the treatment of systemic lupus erythematosus.


Journal

Nanoscale
ISSN: 2040-3372
Titre abrégé: Nanoscale
Pays: England
ID NLM: 101525249

Informations de publication

Date de publication:
24 Mar 2022
Historique:
pubmed: 10 3 2022
medline: 29 3 2022
entrez: 9 3 2022
Statut: epublish

Résumé

Anti-(ds)-DNA antibodies are the serological hallmark of Systemic Lupus Erythematosus (SLE). They assemble in the bloodstream with (ds)-DNA, forming immunocomplexes, which spread all over the body causing, among the other symptoms, lupic glomerulonephritis. Pathological manifestations of the disease may be reduced by destabilizing or inhibiting the formation of the immunocomplexes. In this respect, glycodendrimers showed peculiar interacting abilities towards this kind of biomolecule. Various generations of open-shell maltose-decorated poly(amidoamine) (PAMAM) and poly(propyleneimine) (PPI) dendrimers and two oligopeptides with different polyethylene glycol units were synthesized and characterized, and then tested for their anti-SLE activity. The activity of glycodendrimers and oligopeptides was evaluated in human plasma from patients with SLE, compared to healthy plasma, by means of an enzyme-linked immunosorbent assay (ELISA), and electron paramagnetic resonance (EPR) characterization using spin-label and spin-probe techniques. Different strategies for the immunocomplex formation were tested. The results show that both kinds of glycodendrimers and oligopeptides inhibited the formation of immunocomplexes. Also, a partial breakdown of preformed immunocomplexes was observed. Both ELISA and EPR analyses indicated a better activity of glycodendrimers compared to oligopeptides, the 3

Identifiants

pubmed: 35262128
doi: 10.1039/d1nr06583a
doi:

Substances chimiques

Dendrimers 0
Oligopeptides 0
Maltose 69-79-4
DNA 9007-49-2

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

4654-4670

Auteurs

Sarah Tassinari (S)

Department of Biotechnology and Health Sciences, University of Turin, 10126 Turin, Italy. sarah.tassinari.1994@gmail.com.
Department of Pure and Applied Sciences, Università degli studi di Urbino "Carlo Bo", Urbino 61029, Italy.

Silvia Moreno (S)

Leibniz Institute of Polymer Research Dresden, D-01069 Dresden, Germany. applhans@ipfdd.de.

Hartmut Komber (H)

Leibniz Institute of Polymer Research Dresden, D-01069 Dresden, Germany. applhans@ipfdd.de.

Riccardo Carloni (R)

Department of Pure and Applied Sciences, Università degli studi di Urbino "Carlo Bo", Urbino 61029, Italy.
Knight Cancer Institute, Cancer Early Detection Advanced Research Center (CEDAR), Oregon Health and Science University, USA.

Michela Cangiotti (M)

Department of Pure and Applied Sciences, Università degli studi di Urbino "Carlo Bo", Urbino 61029, Italy.

Maria Francesca Ottaviani (MF)

Department of Pure and Applied Sciences, Università degli studi di Urbino "Carlo Bo", Urbino 61029, Italy.

Dietmar Appelhans (D)

Leibniz Institute of Polymer Research Dresden, D-01069 Dresden, Germany. applhans@ipfdd.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH